Did you mean: CAPUOZZO

Pharmacokinetics of milnacipran in comparison with other antidepressants

C Puozzo, BE Leonard - International clinical …, 1996 - journals.lww.com
Despite the large number of antidepressants currently available, it is still necessary to
develop new drugs that combine the efficacy of the older antidepressant with improved safety, …

Pharmacology and pharmacokinetics of milnacipran

C Puozzo, E Panconi, D Deprez - International clinical …, 2002 - journals.lww.com
: Milnacipran is a dual-action antidepressant drug with equivalent inhibitory action at
noradrenaline and serotonin neuronal reuptake systems. This dual action has been demonstrated …

Oral versus intravenous vinorelbine: clinical safety profile

V Gebbia, C Puozzo - Expert opinion on drug safety, 2005 - Taylor & Francis
The availability of chemotherapeutic drugs administrable by oral route represents a step
forward in the management of cancer patients. Among oral agents, vinorelbine is particularly …

IV busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

…, D Fuller, S Lennon, F Leger, C Puozzo - Bone marrow …, 2004 - nature.com
A retrospective population pharmacokinetic (PPK) analysis was performed in 24 pediatric
patients (PEDS)(0.45–16.7 years old) receiving iv busulfan/cyclophosphamide (iv Bu/Cy 4) …

Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of …

J Gaziev, L Nguyen, C Puozzo, AF Mozzi… - Blood, The Journal …, 2010 - ashpublications.org
… for 30 seconds, 72C for 1 minute 30 seconds) for 35 cycles, and lastly 72C for 10 minutes; …
conditions were 96C for 1 minute, (96C for 10 seconds, 50C for 5 seconds, and 60C for 4 …

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

L Nguyen, F Leger, S Lennon, C Puozzo - Cancer chemotherapy and …, 2006 - Springer
An IV form of busulfan (IV Bu) has recently become available for high dose conditioning
regimen before haematopoietic stem cell transplantation (HSCT). This IV form is expected to …

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer

E Briasoulis, P Pappas, C Puozzo, C Tolis… - Clinical cancer …, 2009 - AACR
C, partial remission of a refractory non–Hodgkin lymphoma treated with MOVIN 60 mg in a …
C, partial remission of a refractory non–Hodgkin lymphoma treated with MOVIN 60 mg in a 68-…

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

…, B Neven, H Zouabi, L Nguyen, C Puozzo - Cancer chemotherapy …, 2008 - Springer
Introduction Oral busulfan clearance is age-dependent and children experience a wide
variability in plasma exposure. BSA- or age-based dosing is used with therapeutic drug …

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

…, L van Doorn, J ter Steeg, M Brandely, C Puozzo… - European journal of …, 2009 - Elsevier
C versus incubation at 4 C for 18 h. The surface membrane staining, in order to identify the
leukocyte subsets, using CD3, CD14 and CD66e in combination with CD45 for lymphocytes, …

[HTML][HTML] Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid …

…, E Raymond, M Campone, FM Delgado, C Puozzo… - Annals of oncology, 2003 - Elsevier
Background Vinflunine is a novel vinca alkaloid obtained by semi-synthesis using super-acidic
chemistry to selectively introduce two fluorine atoms at the 20′ position of vinorelbine. In …
Did you mean to search for: CAPUOZZO